trending Market Intelligence /marketintelligence/en/news-insights/trending/soilrt7om5dju2k8c7ox9a2 content esgSubNav
In This List

Galectin Therapeutics names COO to CEO position

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Galectin Therapeutics names COO to CEO position

Galectin Therapeutics Inc. appointed Harold Shlevin as CEO and president, effective July 6.

Shlevin, who has been Galectin's COO since 2012, succeeds Peter Traber, who has tendered his resignation as president, CEO and chief medical officer.

Previously, Traber decided not to stand for re-election as a director at the annual stockholders meeting.

Norcross, Ga.-based Galectin Therapeutics is a clinical-stage biopharmaceutical company, which engages in the research and development of therapies for fibrotic disease and cancer.